Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Ascendis Pharma A (ASND) over the last 9 years, with Q3 2025 value amounting to $4.6 million.

  • Ascendis Pharma A's Depreciation and Depletion fell 262.28% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 312.9%. This contributed to the annual value of $18.7 million for FY2024, which is 585.22% down from last year.
  • Ascendis Pharma A's Depreciation and Depletion amounted to $4.6 million in Q3 2025, which was down 262.28% from $4.7 million recorded in Q2 2025.
  • Ascendis Pharma A's Depreciation and Depletion's 5-year high stood at $5.2 million during Q4 2023, with a 5-year trough of $4.2 million in Q2 2021.
  • In the last 5 years, Ascendis Pharma A's Depreciation and Depletion had a median value of $4.7 million in 2025 and averaged $4.7 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 9753.5% in 2021, then plummeted by 1037.36% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Depreciation and Depletion (Quarter) stood at $4.8 million in 2021, then fell by 3.02% to $4.6 million in 2022, then rose by 12.47% to $5.2 million in 2023, then decreased by 10.37% to $4.7 million in 2024, then fell by 2.15% to $4.6 million in 2025.
  • Its Depreciation and Depletion was $4.6 million in Q3 2025, compared to $4.7 million in Q2 2025 and $4.7 million in Q1 2025.